OptiBiotix Health

Corporate Governance

Subscribe to our investor alert service and receive all press releases, financial results and other key shareholder messages as soon as they become available.

Products

Microbiome Modulators posters

SweetBiotix Publications

SlimBiome/LeanBiome/OptiBiome Publications

WellBiome Publications

[Header] Publications

Partner Products

Global Partners

Leadership Team

Corporate [Header]

Contact Us

Shareholder Information

Advisors

Commercial Strategy

Market Context

Annual & Interim Reports

AIM Rule 26

Investors

Webinars

Announcements

Media & Presentations

News

Home

First & Second Generation Products

The Science

The Human Microbiome

Microbiome Market Potential

Technology

PT Sans

The Directors recognise the importance of sound corporate governance and the Group complies with the provisions of the Corporate Governance Code for Small and Mid-Size Quoted Companies ("QCA Code"), as published by the Quoted Companies Alliance, to the extent they consider appropriate in light of the Group's size, stage of development and resources.

The Group holds board meetings periodically and as issues arise which require the attention of the Board. The Board is responsible for the governance of the Group, setting the strategic direction of the Group and establishing the policies of the Group. It is the Board's responsibility to oversee and monitor the financial position, the business and affairs of the Group on behalf of the Shareholders, to whom the directors are accountable. The primary duty of the Board is to act in the best interests of the Group and shareholders at all times. The Board also addresses any issues relating to internal control and the Group's approach to risk management.

The Group has established a remuneration committee (the "Remuneration Committee"), an audit and risk committee (the "Audit and Risk Committee") and an AIM Rules compliance committee (the "AIM Compliance Committee") with formally delegated duties and responsibilities.

The Remuneration Committee, which comprises Neil Davidson as Chairman and Sean Christie, meets not less than twice each year. The committee is responsible for the review and recommendation of the scale and structure of remuneration for senior management, including any bonus arrangements or the award of share options with due regard to the interests of the shareholders and the performance of the Group.

The Audit and Risk Committee, which comprises Sean Christie as Chairman and Neil Davidson meets not less than twice a year. The committee is responsible for making recommendations to the Board on the appointment of auditors and the audit fee and for ensuring that the financial performance of the Group is properly monitored and reported. In addition, the Audit and Risk Committee receives and reviews reports from management and the auditors relating to the interim report, the annual report and accounts and the internal control systems of the Group.

The AIM Compliance Committee, which comprises Neil Davidson as Chairman and Sean Christie, is responsible for ensuring that (i) the Board remains at all times fully cognisant of its obligations under the AIM Rules for Companies and (ii) regular contact is maintained with the Company's nominated adviser so that it is kept up to date with all relevant developments at the Company.

The Group has adopted and operates a share dealing code governing the share dealings in the Company's shares of the Board and applicable employees with a view to ensuring compliance with the AIM Rules.

The Directors recognise the importance of sound corporate governance and the Directors observe the recommendations of the QCA Corporate Governance Code

The QCA Code is constructed around ten broad principles (accompanied by an explanation of what these principles entail, under 'application') and a set of disclosures. The Code states what is considered to be appropriate arrangements for growing companies and asks companies to provide an explanation about how they are meeting the principles through the prescribed disclosures.

The table below sets out the principles and the application recommended by the QCA code. It then sets out how OptiBiotix complies with these requirements, departures from code and provides links to appropriate disclosures. These are based upon the recommended disclosures provided in the QCA code.

These disclosures were last reviewed on 24 June 2025.